04.06.2022 - Capital infusion into the Company aims to further increase near-term production throughput to meet the growing backlog and increased demand for both its Limestone and Aquasport Brands through 2023.NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE . Seite 1
/PRNewswire/ Canntab Therapeutics Limited ("Canntab" or the "Company") (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1), the leading innovator in cannabinoid and terpene.
TORONTO, Feb. 1, 2022 /PRNewswire/ Canntab Therapeutics Limited , the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to. | February 2, 2022